GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Piotroski F-Score
中文

AngioDynamics (AngioDynamics) Piotroski F-Score : 3 (As of Apr. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AngioDynamics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for AngioDynamics's Piotroski F-Score or its related term are showing as below:

ANGO' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of AngioDynamics was 7. The lowest was 2. And the median was 5.


AngioDynamics Piotroski F-Score Historical Data

The historical data trend for AngioDynamics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Piotroski F-Score Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 2.00 5.00 3.00 4.00

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 4.00 5.00 4.00 3.00

Competitive Comparison of AngioDynamics's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, AngioDynamics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Net Income was -21.467 + 45.884 + -29.048 + -187.736 = $-192.4 Mil.
Cash Flow from Operations was 15.954 + -25.899 + 5.266 + -12.526 = $-17.2 Mil.
Revenue was 91.074 + 78.679 + 79.073 + 75.182 = $324.0 Mil.
Gross Profit was 46.359 + 40.06 + 40.262 + 35.861 = $162.5 Mil.
Average Total Assets from the begining of this year (Feb23)
to the end of this year (Feb24) was
(542.849 + 532.637 + 493.949 + 499.623 + 324.842) / 5 = $478.78 Mil.
Total Assets at the begining of this year (Feb23) was $542.8 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Current Assets was $196.9 Mil.
Total Current Liabilities was $85.9 Mil.
Net Income was -6.266 + -13.004 + -8.486 + -9.485 = $-37.2 Mil.

Revenue was 86.998 + 81.537 + 85.429 + 80.712 = $334.7 Mil.
Gross Profit was 46.455 + 42.305 + 45.078 + 40.504 = $174.3 Mil.
Average Total Assets from the begining of last year (Feb22)
to the end of last year (Feb23) was
(543.178 + 552.751 + 557.652 + 558.207 + 542.849) / 5 = $550.9274 Mil.
Total Assets at the begining of last year (Feb22) was $543.2 Mil.
Long-Term Debt & Capital Lease Obligation was $49.8 Mil.
Total Current Assets was $152.6 Mil.
Total Current Liabilities was $69.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AngioDynamics's current Net Income (TTM) was -192.4. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AngioDynamics's current Cash Flow from Operations (TTM) was -17.2. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Feb23)
=-192.367/542.849
=-0.35436558

ROA (Last Year)=Net Income/Total Assets (Feb22)
=-37.241/543.178
=-0.06856132

AngioDynamics's return on assets of this year was -0.35436558. AngioDynamics's return on assets of last year was -0.06856132. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

AngioDynamics's current Net Income (TTM) was -192.4. AngioDynamics's current Cash Flow from Operations (TTM) was -17.2. ==> -17.2 > -192.4 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Feb24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Feb23 to Feb24
=0/478.78
=0

Gearing (Last Year: Feb23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Feb22 to Feb23
=49.807/550.9274
=0.09040574

AngioDynamics's gearing of this year was 0. AngioDynamics's gearing of last year was 0.09040574. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Feb24)=Total Current Assets/Total Current Liabilities
=196.907/85.874
=2.29297576

Current Ratio (Last Year: Feb23)=Total Current Assets/Total Current Liabilities
=152.574/69.632
=2.19114775

AngioDynamics's current ratio of this year was 2.29297576. AngioDynamics's current ratio of last year was 2.19114775. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

AngioDynamics's number of shares in issue this year was 40.234. AngioDynamics's number of shares in issue last year was 39.509. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=162.542/324.008
=0.50166045

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=174.342/334.676
=0.5209277

AngioDynamics's gross margin of this year was 0.50166045. AngioDynamics's gross margin of last year was 0.5209277. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Feb23)
=324.008/542.849
=0.5968658

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Feb22)
=334.676/543.178
=0.61614425

AngioDynamics's asset turnover of this year was 0.5968658. AngioDynamics's asset turnover of last year was 0.61614425. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AngioDynamics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

AngioDynamics  (NAS:ANGO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


AngioDynamics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421